Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography

European Journal of Nuclear Medicine

Volumn 25, Issue 7, 1998, Pages 721-728

  Stumpe, K D M ^a   Urbinelli, M ^a   Steinert, H C ^a   Glanzmann, Ch ^a   Buck, A ^a   Von Schulthess, G K ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Computed tomography; Lymphoma staging; Whole body positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PELVIS FLOOR; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCAR; SKULL BASE; STAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE-BODY COUNTING;

COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; DISEASE CONTROL; ELECTRONS; MEDICAL IMAGING; ONCOLOGY; POSITRONS;

COMPUTED TOMOGRAPHY; FLUORODEOXYGLUCOSE; HODGKIN'S DISEASE; LYMPHOMA STAGING; NON-HODGKIN LYMPHOMA; SENSITIVITY AND SPECIFICITY; SKULL BASE; TRANSAXIAL; WHOLE-BODY; WHOLE-BODY POSITRON EMISSION TOMOGRAPHY;

POSITRON EMISSION TOMOGRAPHY;

EID: 0031869324     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050275     Document Type: Article

References (23)

1. Royal HD. Clinical applications of positron emission tomography in cancer: the good, the had and the ugly [editorial]. J Nucl Med 1992; 33: 330-332.
2. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
3. 18F]-FDG: correlation with CT. Radiology 1994; 190: 111-116.
4. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
5. Steinert HC, Huch Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
6. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
7. Bengel FM, Ziegler SI, Avril N, et al. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med 1997 24: 1091-1098.
8. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teräs M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32: 1211-1218.
9. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
10. Okada J, Yoshikawa K, Imazeki K, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation and uptake with prognosis. J Nucl Med 1991; 32: 686-691.
11. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288-292.
12. Shirkoda A. Lymphoma of the solid abdominal viscera. Radiol Clin North Am 1990; 28: 785-799.
13. Bares R, Altehoefer C, Cremerius U, et al. FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy [abstract]. J Nucl Med 1994; 35: 131P.
14. Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992; 326: 678-687.
15. Armitage JO, Cheson BD. Interpretation of clinical trials in DLCL. J Clin Oncol 1988; 6: 1335-1347.
16. Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34: 1706-1710.
17. Jerusalem G, Fassotte MF, Paulus P, et al. Whole-body positron emission tomography for staging, response evaluation and follow-up of Hodgkin's disease and non-Hodgkin lymphoma. Blood 1995; 86 Suppl 1: 534a.
18. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med 1994; 8: 109-113.
19. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [letter]. Lancet 1988; 1: 292.
20. Moog F, Bangerter M, Diederichs CD, et al. Lymphoma: role of whole-body-FDG-PET in nodal staging. Radiology 1997; 203: 795-800.
21. Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 5: 637-640.
22. Schonberger JA, Stollfuss JC, Kocher F, et al. Whole-body 18-FDG-PET for staging of malignant lymphomas [abstract]. Eur J Nucl Med 1994; 21: 727.
23. Wahl RL, Hawkins RA, Larson SM, et al. Proceedings of a National Cancer Institute workshop: PET in oncology - a clinical research agenda. Radiology 1994; 193: 604-606.